Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 20134337.
- Also identified by DOI 10.1097/JOM.0b013e3181cb5b10.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To assess effects of antidepressant treatment compliance on health care and workplace costs. By using workplace survey data linked to two employers' health care claims, employees with depression/antidepressant claims were categorized into noncompliant/compliant groups. Annualized costs were compared between compliance groups, for the employees with antidepressant use and a subset diagnosed with depression. Among antidepressant users (N = 1224), medical costs were not statistically different for compliant versus noncompliant patients; drug costs were higher for compliant patients, primarily because of antidepressants' costs. Similar associations were observed among depressed patients (N = 488). Absenteeism costs were lower for compliant patients with antidepressant use ($3857 vs $4,907, P = 0.041) and among depressed patients ($3976 vs $5899, P = 0.047). Presenteeism costs were higher for depressed compliant patients ($19,170 vs $15,829, P = 0.011). Increased compliance with antidepressants is significantly associated with reduced absenteeism costs.
Medical subject headings
- Antidepressive Agents
- Drug Costs
- Employer Health Costs
- Patient Compliance